EGFR复合少见突变阳性的非小细胞肺癌患者的临床特征及疗效分析

The clinical characteristics and treatment response of patients with EGFR complex rare mutations

目的:分析非小细胞肺癌患者中表皮生长因子受体(EGFR)突变为包含少见突变的复合突变患者的临床特征与治疗效果,为EGFR复合少见突变阳性的非小细胞肺癌患者的治疗提供依据。方法:回顾性分析22例EGFR复合少见突变阳性的非小细胞肺癌患者的病历资料及治疗经过。比较患者EGFR基因突变类型、临床资料特征及治疗效果。结果:在我院2014年-2018年病理科检测的EGFR突变阳性的3224名患者当中,EGFR复合突变共147例,占比为4.56%,而复合少见突变患者共27例,占比0.84%。晚期复合少见突变患者中有11名使用EGFR酪氨酸激酶抑制剂(TKI)治疗,对这些患者的治疗用药及疗效分析后,使用一代TKI治疗患者6人,中位无进展生存时间(PFS)为8.4个月,二代TKI治疗患者5人,中位PFS为7.2月,两组之间无明显统计学差别。结论:EGFR复合少见突变的患者使用一代或二代EGFR-TKI治疗疗效无明显差别。

Objective:To analyze clinical characteristics and treatment outcomes of the non-small cell lung cancer patients,who had EGFR complex rare mutations,to get more information and give better treatment for these patients.Methods:The clinical data and treatment of 22 patients who had EGFR complex rare mutations in our hospital were collected and analyzed retrospectively.Results:There are 3 224 EGFR mutation positive patients in all the tested samples in our hospital during 2014 to 2018.There was the complex mutations positive in 147 patients(4.56%) and 27 patients(0.84%) with complex rare mutations positive.In these complex rare mutation positive patients,there were 11 patients had received EGFR-TKI treatment.Six patients used first generation TKI as treatment, and the medium PFS was 8.4 months.The other 5 patients used second generation TKI as treatment and the medium PFS was 7.2 months.There was no significant difference between these two groups.Conclusion:For the EGFR complex rare mutations positive patients,there is no difference between the treatment of first or second generation TKI.